|
| | Ranimustine Basic information |
| Product Name: | Ranimustine | | Synonyms: | 1-(2-chloroethyl)-1-nitroso-3-[[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-methoxy-oxan-2-yl]methyl]urea;Cymerin;MCNU;Methyl 6-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-6-deoxy-α-D-glucopyranoside;NSC-0270516;Ranomustine;Thymerin;Methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-α-D-glucopyranoside | | CAS: | 58994-96-0 | | MF: | C10H18ClN3O7 | | MW: | 327.72 | | EINECS: | | | Product Categories: | | | Mol File: | 58994-96-0.mol |  |
| | Ranimustine Chemical Properties |
| Melting point | 111-112° | | alpha | D20 +93.2° (c = 0.5 in methanol) (Kimura); D25 +73.2° (c = 0.3 in methanol) (Kimura, Sekine) | | density | 1.69±0.1 g/cm3(Predicted) | | solubility | Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) | | pka | 10.59±0.46(Predicted) | | form | Solid | | color | Off-White to Pale Yellow | | CAS DataBase Reference | 58994-96-0(CAS DataBase Reference) |
| Toxicity | LD50 in male rats (mg/kg): 42 i.p., 42 i.v., 50 orally (Kimura) |
| | Ranimustine Usage And Synthesis |
| Description | Ranimustine, a new nitrosourea derivative, is a water soluble antitumor agent with low
hematological toxicity and diabetogenic effect. It is reportedly effective in the treatment
of hematologic malignancies, especially the myeloproliferative disorders. | | Originator | Tokyo Tanabe (Japan) | | Uses | Glucocorticoid with low systemic absorption anti-inflammatory agent | | Definition | ChEBI: Ranimustine is an organic molecular entity. | | Brand name | Cymerine |
| | Ranimustine Preparation Products And Raw materials |
|
